Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.

Ciotti, John R; Grebenciucova, Elena; Moss, Brandon P; Newsome, Scott D

Ciotti, John R; Grebenciucova, Elena; Moss, Brandon P; Newsome, Scott D.

Ciotti JR; Washington University School of Medicine, St. Louis, MO, USA.
Grebenciucova E; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Moss BP; Cleveland Clinic Mellen Center for MS, Cleveland, OH, USA.
Newsome SD; Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ann Neurol ; 88(6): 1062-1064, 2020 12.

Article in English | MEDLINE | ID: covidwho-1017905

Subject(s)

Coronavirus Infections/prevention & control; Immunologic Factors/therapeutic use; Multiple Sclerosis/drug therapy; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; Betacoronavirus; COVID-19; Clinical Decision-Making; Coronavirus Infections/epidemiology; Coronavirus Infections/immunology; Delivery of Health Care; Humans; Pneumonia, Viral/epidemiology; Pneumonia, Viral/immunology; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Immunologic Factors / Multiple Sclerosis Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Ann Neurol Year: 2020 Document Type: Article Affiliation country: Ana.25907

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google